Hematuria and IgA Nephropathy

  • Giuseppe D’amico

Abstract

Persistent asymptomatic microscopic hematuria with mild proteinuria, usually found by a chance urinalysis, or, in a subgroup of patients, recurrent episodes of macroscopic hematuria closely associated with respiratory tract infections are the presenting clinical symptoms of the most common idiopathic chronic glomerular disease. This illness is characterized morphologically by diffuse mesangial deposition of IgA with mesangial expansion and proliferation and is therefore called IgA nephropathy or Berger’s disease (since it was first described by Berger, a French investigator, in 1968).

Keywords

Sodium Cromoglycate Microscopic Hematuria Macroscopic Hematuria Mesangial Proliferation Mesangial Deposition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D’Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: 709–727, 1987.PubMedGoogle Scholar
  2. 2.
    Schena FP: A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89: 209–215, 1990.PubMedCrossRefGoogle Scholar
  3. 3.
    Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 84: 129–132, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Moore RH, Hitman GA, Sinico RA, Mustonen J, Medkraft J, Lucas EY, Richards NT, Yenning MC, Cunningham J, Marsh FP, D’Amico G: Immunoglobulin heavy chain switch region gene polymorphisms in glomerulonephritis. Kidney Int 38: 332–336, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Li PKT, Burns AP, So AKL, Pusey CD, Feehally J, Rees AJ: The DQw7 allele at the HLA-DQB locus is associated with susceptibility to IgA nephropathy in Caucasians. Kidney Int 39: 961–965, 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    Crowley-Nowick PA, Julian BA, Wyatt RJ, Galla JH, Wall BM, Warnock DG, Mestecky J, Jackson S: IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int 39: 1218–1224, 1991.PubMedCrossRefGoogle Scholar
  7. 7.
    D’Amico G: Clinical features and natural history in adults with IgA nephropathy. Am J Kidney Dis 12: 353–357, 1988.PubMedGoogle Scholar
  8. 8.
    D’Amico G, Colasanti G, Barbiano di Belgioioso G, et al.: Long-term follow-up of IgA mesangial nephropathy. Clinico-histological study in 374 patients. Semin Nephrol 7: 355–358, 1987.PubMedGoogle Scholar
  9. 9.
    Emancipator SN: Immunoregolatory factors in the pathogenesis of IgA nephropathy. Kidney Int 38: 1216, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Feehally J: Immune mechanisms in glomerular IgA deposition. Nephrol Dial Transplant 3: 361–378, 1988.PubMedGoogle Scholar
  11. 11.
    Rifai A: The parallax of IgA immune complex associated nephropathy. J Nephrol 2: 127–134, 1989.Google Scholar
  12. 12.
    de Caestecker MP, Bottomley M, Telfer BA, Hutchinson IV, Vose BM, Ballardie FW: Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. Kidney Int 44: 1298–1308, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Coppo R, Emancipator S: Pathogenesis of IgA nephropathy: established observations, new insights and perspectives in treatment. J Pathol 7: 5–15, 1994.Google Scholar
  14. 14.
    Bené MC, Hurault de Ligny B, Kessler M, Foliguet, Faure GC: Tonsils in IgA nephropathy. Contrib Nephrol 104: 153161, 1993.Google Scholar
  15. 15.
    Kincaid-Smith PS, Nicholls K: Mesangial IgA nephropathy. Am J Kidney Dis 3: 90–102, 1983.PubMedGoogle Scholar
  16. 16.
    Coppo R, Roccatello D, Amore A, Quattrocchio G, Molino A, Gianoglio B, Amoroso A, Bajardi P, Piccoli G: Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 33: 72–86, 1990.PubMedGoogle Scholar
  17. 17.
    Ferri C, Puccini R, Longombardo G, Paleologo G, Migliorini P, Moriconi L, Pasero G, Cioni L: Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrol Dial Transplant 8: 1193–1198, 1993.PubMedGoogle Scholar
  18. 18.
    Bazzi C, Sinico RA, Petrini C, Rizza V, Torpia R, Arrigo G, Ragni A, D’Amico G: Low doses of drugs able to alter intestinal mucosal permeability to food antigens (5-aminosalicylic acid and sodium cromoglycate) do not reduce proteinuria in patients with IgA nephropathy: a preliminary noncontrolled trial. Nephron 61: 192–195, 1992.PubMedCrossRefGoogle Scholar
  19. 19.
    Egido J, Rivera F, Sancho J, Barat AM, Hernando L: Phenytoin in IgA nephropathy: a long-term controlled trial. Nephron 38: 30–39, 1984.PubMedCrossRefGoogle Scholar
  20. 20.
    Clarkson AR, Seymour AE, Woodroffe AJ, McKenzie PE, Chan L, Wootton AM: Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 13: 215–218, 1980.PubMedGoogle Scholar
  21. 21.
    Chan MK, Kwan SYL, Chan KW, et al.: Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J.Kidney Dis 9: 417–421, 1987.PubMedGoogle Scholar
  22. 22.
    Miura M, Endoh M, Nomoto Y, Sakai H: Long-term effect of urokinase therapy in IgA nephropathy. Clin Nephrol 32: 209216, 1989.Google Scholar
  23. 23.
    Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with neph rotic syndrome: a long-term controlled trial. Clin Nephrol 26: 174–180, 1986.PubMedGoogle Scholar
  24. 24.
    Woo KT, Edmondson RPS, Yap HK, Wu AYT, Chiang GSC, Lee EJC, Pwee HS, Lim CH: Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 27: 56–64, 1987.PubMedGoogle Scholar
  25. 25.
    Walker RG, Yu SH, Owen JE, Kincaid-Smith P: The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 34: 103–107, 1990.PubMedGoogle Scholar
  26. 26.
    Hamazaki T, Tateno S, Shichido H: Eicosapentanoic acid and IgA nephropathy. Lancet i: 1017–1018, 1984.Google Scholar
  27. 27.
    Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a ten-year prospective trial. Clin Nephrol 31: 128–131, 1989.PubMedGoogle Scholar
  28. 28.
    Cheng IKP, Chan PCK, Chan MK: The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 5: 241–246, 1990.PubMedCrossRefGoogle Scholar
  29. 29.
    Donadio JV: Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 66: 1018–1028, 1991.PubMedCrossRefGoogle Scholar
  30. 30.
    Lai KN: A short-term controlled trial of cyclosporine A in IgA nephropathy. Transplant Proc 20: 297–303, 1988.PubMedGoogle Scholar
  31. 31.
    Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M: Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 48: 12–17, 1988.PubMedCrossRefGoogle Scholar
  32. 32.
    Kobayashi Y, Fujii K, Hiki Y, Tateno S: Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med 234: 935–943, 1986.Google Scholar
  33. 33.
    Waldo FB, Alexander R, Wyatt RJ, Kohaut EC: Alternate-day prednisone therapy in children with IgA-associated nephritis. Am J Kidney Dis 1: 55–60, 1989.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Giuseppe D’amico
    • 1
  1. 1.Divisione di NefrologiaOspedale San Carlo Borromeo-MilanoMilanoItaly

Personalised recommendations